secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001193125-24-161151
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics appoints Garry Nicholson to board, Stephen Biggar named chair; Barberich retires
--------------------------------------------------------------------------------

- Timothy Barberich resigned as director and Chair effective June 12, 2024; no disagreement cited.
- Stephen Biggar, M.D., Ph.D., assumed Chair role; Nicholson appointed to Board effective same date.
- Garry Nicholson brings 35+ years oncology experience, including former President of Pfizer Oncology.
- Stockholders approved Amended 2021 Equity Plan adding 2M shares; non-employee directors granted options for 308,750 shares at $8.88.
- Nicholson receives initial option for 71,250 shares, vesting over one year or next annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524161151/0001193125-24-161151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524161151/d785285d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-161151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer